Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (332)	4/29/2003 2:05:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ILXO Hs been up 15.78% today (0nly 14.3% at present <g>) after reporting that sales of CAMPATH reached a record $13.9M in the 1st Q.(That was 19% more than on the previous Q, but only 10% more than on the 1st Q last year.<g>) The loss for the Q was $24.9 M (0.76/share) which included $16.5M from a "settlement of a contract dispute."<g> Besides CAMPATH, ILXO has four Oncology products in trials and others in "pre-clinical" programs.(Eflonthrine in Phase II; Clofarabine; Apomine which is a potential competitor for Fosamax & Actonel; and ILX-651 in "pre-clinical" stage. The stock has almost doubled since March 17 and today is trading above its Nov.-Dec. double top at the 11.20 level. siliconinvestor.com siliconinvestor.com Bernard